H.C. Wainwright Reiterates Buy on Marinus Pharmaceuticals, Raises Price Target to $6

H.C. Wainwright analyst Douglas Tsao reiterates Marinus Pharmaceuticals (NASDAQ:MRNS) with a Buy and raises the price target from $5 to $6.

Benzinga · 01/10/2020 15:34

H.C. Wainwright analyst Douglas Tsao reiterates Marinus Pharmaceuticals (NASDAQ:MRNS) with a Buy and raises the price target from $5 to $6.